Get great content like this right in your inbox.

Amazon kept up its tradition on Cyber Monday.

The online giant said that Cyber Monday was the single biggest shopping day in its history, based on the number of items ordered worldwide. Cyber Monday has been Amazon's top sales day for several years, outpacing the previous Prime Day and Black Friday. Amazons best-selling products on Cyber Monday in the U.S. included Echo Dot, Fire TV Stick with Alexa Voice Remote, Play-Doh Sweet Shoppe Cookie Creations, Keurig K-Cafe Coffee Maker and Lego City Ambulance Helicopter 60179 Building Kit.

In keeping with its policy of rarely (if ever) revealing exact numbers, Amazon said that hundreds of millions of products were ordered worldwide between Thanksgiving and Cyber Monday. Shoppers purchased millions more Amazon devices over the holiday period compared to the same period last year, the said, with Echo Dot and Fire TV Stick 4K with Alexa Voice Remote ranking as the top-selling items.

In other holiday weekend highlights from Amazon:

Read the original post:
Amazon set a record of its own on Cyber Monday - Chain Store Age

Recommendation and review posted by Bethany Smith

Its known as the silent killer.Symptoms begin with muscle weakness until eventually ones muscles are completely deteriorated.Its called muscular dystrophy, andit affects one in every 5,000 males.

Because it is rare, muscular dystrophy has not received the attention and research funding of more common diseases, according to University of Cincinnati researchers.

My experience is that if a person does not have a family member or relative or friend affected by muscular dystrophy, then they typically do not know about [muscular dystrophy], saysHani Kushlaf, associate professor of neurology and pathology, who sees patientswith the disease.

UC researchers are trying to change this lack of transparency by sharing their experiences with the disease. They understand that the goal of finding a cure for muscular dystrophy begins with awareness.

One person who truly understands the disease from both a medical professional standpoint and from personal experience is John Quinlan, director of the neuromuscular center at UCs Neuroscience Institute, who teaches as a professor and sees patients as a practicing neurologist with UC Health.

In an interview with UC Health, Quinlan said he chose neurology because he believed it was a field where there was a lot of puzzle-solving of complicated diagnoses such as his own muscular dystrophy.

Because I have some physical limitations, I saw when I was a medical student that I wasnt going to go into surgical areas, and so that made me think of the more internal medicine and subspecialties, Quinlan said.

Phillip Witcher, who is completing his doctorate at the College of Medicine, had Quinlan as a professor. He said he didnt know Quinlan had muscular dystrophy when he met him.

I just knew that he was in a wheelchair and that he was a smart professor, Witcher said.

Witcher himself is doing research on muscular dystrophy. He is in his first year of research on muscle cell fusion in the Doug Millay lab at Cincinnatis Childrens Hospital.

Witchers research focuses on themyomaker and myomergerm the proteins within muscular cells with the hope of helping patients with muscular dystrophy through cell therapy.

Muscular Dystrophy is caused bygenetic mutationsthat interfere with the production of proteins that are needed to build and maintain healthy muscles, according to the Muscular Dystrophy Association (MDA).

Imagine running a race. Your muscles are tired, and to recover they need to build new proteins to regain strength.The feeling for patients with muscular dystrophy is similar, except they never regain it. The reason muscular dystrophy is known as the silent killer is that this muscle deterioration is a slow process. The body gradually evolves into a physical shell.

Muscle weakness often leads to the curving of the spine, forcing many with it into a wheelchair if their failing muscles didnt force them into one already.It leads to the shortening of muscles and tendons and severe breathing issues. Eventually this advances to paralyzed mobility in most of the body. There is no cure.

One of the most intense and aggressive forms of muscular dystrophy is Duchenne Muscular Dystrophy (DMD). Muscle loss and weakness is caused by alterations ina protein calleddystrophin, which helps keep muscle cells whole. Symptoms for those who have DMD first present themselves in children at an early age and progressively get worse.

But today, people with DMD have a longer lifespan because research breakthroughs have created drugs and treatment options. Symptoms can kill. These treatment options help with treating the symptoms from muscular dystrophy. According to MDA,the life expectancy for those born with DMD is in the early 30s because of advances in cardiac and respiratory care.

We live in an exciting time for (treating) muscular dystrophies, Kushlaf said.

UC researchers agree: to find a cure, awareness needs to be shared and stories need to be told.

Witcher said diseases with more physical and behavioral cues, such as breast cancer, get media attention. Millions of people see the physical signs of chemotherapy of breast cancer patients, such as hair loss and are the Susan G. Komen Breast Cancer Foundation, the largest and best-funded cancer organization.

I dont think it is just the lack of awareness, Kushlaf said. Federal funding for research is typically allocated for common disorders more than rare disorders. Therefore, researchers of common diseases are more likely to get funded than those who study rare diseases.

Still, Kushlaf said awareness for Amyotrophic Lateral Sclerosis (ALS) increased during the viral ALS bucket challenge, which led to significant philanthropy and funding of ALS research projects.

Kushlaf said researchers are hopeful of a cure. The FDA approval of gene therapy for spinal muscular atrophy offer hope for a cure or significant improvements, he said. The next steps are to find out the effect of gene therapies on muscular dystrophies.

Curing muscular dystrophy is a complex dilemma, as the problem lies in the genetic makeup of the individual, Kushlaf said. The advent of gene therapy offers hope for a cure.

Previous therapies have had limited success because they only helped slow the progression of the dystrophy, according to Kushlaf.

Witcher said therapies for muscular dystrophy have evolved, but most are only treating symptoms and not the disease itself.

And thats where were really stuck right now figuring out how to move forward as far as treating the disease and not just the symptoms, Witcher said.

See the original post:
Finding strength in the fight against muscular dystrophy - The News Record

Recommendation and review posted by Bethany Smith

BORIS Johnsons punishing 16-hour days are fuelled by porridge, flapjacks and endless cups of coffee.

He has also given up booze and confesses he reads ancient Greek poetry before bed.

The Sun spent a full day on the campaign trail with the PM, as he criss-crossed the country in a bid to whip up votes.

For our Day in the Life video diary, Mr Johnson confided about everything from organising a Nato summit to the personal abuse he gets from actor Hugh Grant.

On December 12, Mr Johnson will either get majority he craves to deliver Brexit, or be the second shortest-serving PM in history. With so much at stake, he packs in as much as he can to his breakneck daily campaigning schedule:

6.10am: Boris walks Jack Russell Dilyn then eats a large bowl of porridge at the flat he shares with his girlfriend Carrie Symonds at No11 Downing Street.

After breakfast he takes his first phone calls from four key aides and swaps text messages with confidante Cabinet ministers.

8am: He leaves leaves Downing Street for the nearby Conservative HQ. Election campaign director Isaac Levido has been at his desk from 5am and briefs Mr Johnson on daily tactics to attack Labour.

11am: A motorcade rushes the PM across central London so he can attend a vigil for the victims of the London Bridge terror attack. He is joined by Home Secretary Priti Patel, London Mayor Sadiq Khan and Labour leader Jeremy Corbyn.

The mornings campaign schedule was ripped up to allow politicians to pay their respects.

11.35am: An 81-mile dash down the M3 to Southampton. The PMs motorcade drives at high speed, bumper to bumper, repeatedly accelerating and braking heavily. But Mr Johnson insists he never gets car sick, saying: Im really too busy writing speeches, or thinking about the next thing.

Those guys on the motorbikes are brilliant though, what they do to get us through traffic fast. I do feel a bit ashamed sometimes, but it is essential. You just need to get from A to B fast.

1.10pm: A tour of Southamptons port taking in the control room and dockside where he meets workers, then out in a patrol boat to inspect ships at berth. Southampton Itchen is a key marginal, which the Tories held by just 31 votes in 2017.

Boris says he loves getting out, and takes every opportunity he can to promote Brexit. He declares: "When a big ship comes into this port, they make no distinction whether it comes from the EU or anywhere else in the world.

The procedures are exactly the same. It just goes to show that some of the anxiety about leaving the EU is very often overdone.

2.45pm: A round of local and national TV interviews. Campaign chiefs ensure he does this every day to dominate the news cycle. Mr Johnson faces questions on the London Bridge horror and pro-Remain actor Hugh Grant, campaigning for Lib Dems.

How does he feel when Grant, who played the Prime Minister in Love Actually, says the election is a national emergency and a Tory majority would be catastrophic?

Boris insists: Water off a ducks back. Of course a lot of people care very strongly about Brexit. I make an exception for the gentleman you mention, but most people I meet are frustrated about the paralysis in Parliament.

3.10pm: Before returning to London, the PM is briefed on the days developments for the Government. A senior No10 official always accompanies him on campaign trips in case there are any urgent decisions which need to be made. How does he handle constantly spinning all those plates?

Boris explains: I find it constantly stimulating. Obviously there is a different level of focus. Some of the geopolitical stuff does require a different tone and a different pitch. But what youre really doing is trying to bring people together.

5.15pm: Boris is back at Tory HQ in Westminster, for a meeting with senior Government officials about the upcoming Nato summit which Britain is hosting.

He sees his job this week as both cheerleader and peacemaker and says: Some people want to chip a bit of paint off Nato every now and then. Not everybody in France has been an uncritical admirer, so we have to show why it works.

6.10pm: The PMs motorcade heads 68-miles to Colchester, where he will address a Tory rally. He has been at it for ten hours. How does he keep going?

The PM admits: I sometimes succumb to flapjacks, which are not medically recommended. And I seem to be able to drink an unlimited amount of coffee without impeding my ability to sleep at the end of the day.

He insists that he seldom tires, describing himself as hard as nails and built from steel springs. Mr Johnson adds: I have a lot of energy. I think its genetic.

8.35pm: Traffic out of London is heavy and Boris is late for the rally at a Colchester printworks. Adoring party members cheer and laugh at his regular jokes. How does he pump himself up?

Boris says: I have a huge sense of responsibility for getting this right. This is it. There is a very short time left. There is a very real risk of another hung Parliament. On the way out two workers with mohicans, accost him for a selfie.

Live Blog

ELECTION NEWS Voters back Boris Johnson's tough defence stance as he hosts NATO leaders

CUT DOWN TO SIZE Corbyn humiliated after failing to confront Trump over NHS trade deal

ALL THE PRESIDENT'S FRIENDS Trump welcomed by the Queen and Charles at Buckingham Palace

ALL ABOARD Boris plans to plough 4.2bn into overhauling England's trains and bus services

POLL POSITION General Election polls tracker and odds - who will win in 2019?

10.20pm: His armour-plated Jaguar pulls up at the back entrance of No11 and Boris is home. What does he do to relax in those few moments before bed?

He gives an embarrassed giggle: A few quadratic equations, and a bit of Greek lyric poetry. Nothing complicated. Its a terrible confession but I do. Everybody should. Most might pour a stiff drink but Boris insists his self-imposed booze ban is still firmly in place.

He insists: Ive had to wet my whistle three times in this campaign but I will not swallow. I cant. We have to get Brexit done, unleash the potential. He turns and says: Night night, see you.

Read this article:
The Sun joins Boris Johnsons gruelling 16-hour day on the campaign trail - The Sun

Recommendation and review posted by Bethany Smith

news, latest-news

Russian scientists have showed off a prehistoric puppy, believed to be 18,000 years old, that was found in permafrost in the country's Far East. Discovered in 2018 in a lump of frozen mud near the city of Yakutsk, the puppy is unusually well preserved, with its hair, teeth, whiskers and eyelashes still intact. "This puppy has all its limbs, pelage - fur, even whiskers. The nose is visible. There are teeth. We can determine due to some data that it is a male," Nikolai Androsov, director of the Northern World private museum where the remains are stored, said at the presentation at the Yakutsk's Mammoth Museum which specialises in ancient specimens. In recent years, Russia's Far East has provided many riches for scientists studying the remains of ancient animals. As the permafrost melts, affected by climate change, more and more parts of woolly mammoths, canines and other prehistoric animals are being discovered. Often it is mammoth tusk hunters who discover them. "Why has Yakutia come through a real spate of such unique findings over the last decade? First, it's global warming. It really exists, we feel it, and local people feel it strongly. Winter comes later, spring comes earlier," Sergei Fyodorov, scientist with the North Eastern Federal University, told The Associated Press. "And the second very serious, deep reason, of why there a lot of finds is the very high price of mammoth tusk in the Chinese market." When the puppy was discovered, scientists from the Stockholm-based Centre for Palaeogenetics took a piece of bone to study its DNA. "The first step was of course to send the sample to radio carbon dating to see how old it was and when we got the results back it turned out that it was roughly 18,000 years old," Love Dalen, professor of evolutionary genetics at the center, said in an online interview. Further tests, however, left the scientists with more questions than answers - they could not definitively tell whether it was a dog or a wolf. Dalen said scientists were about to do a third round of genome sequencing, which might solve the mystery. Australian Associated Press

https://nnimgt-a.akamaihd.net/transform/v1/crop/frm/silverstone-feed-data/4ec5d096-b112-41b6-be92-003b2d13de51.jpg/r0_74_800_526_w1200_h678_fmax.jpg

December 3 2019 - 11:46AM

Russian scientists have showed off a prehistoric puppy, believed to be 18,000 years old, that was found in permafrost in the country's Far East.

Discovered in 2018 in a lump of frozen mud near the city of Yakutsk, the puppy is unusually well preserved, with its hair, teeth, whiskers and eyelashes still intact.

"This puppy has all its limbs, pelage - fur, even whiskers. The nose is visible. There are teeth. We can determine due to some data that it is a male," Nikolai Androsov, director of the Northern World private museum where the remains are stored, said at the presentation at the Yakutsk's Mammoth Museum which specialises in ancient specimens.

In recent years, Russia's Far East has provided many riches for scientists studying the remains of ancient animals.

As the permafrost melts, affected by climate change, more and more parts of woolly mammoths, canines and other prehistoric animals are being discovered. Often it is mammoth tusk hunters who discover them.

"Why has Yakutia come through a real spate of such unique findings over the last decade? First, it's global warming. It really exists, we feel it, and local people feel it strongly. Winter comes later, spring comes earlier," Sergei Fyodorov, scientist with the North Eastern Federal University, told The Associated Press.

"And the second very serious, deep reason, of why there a lot of finds is the very high price of mammoth tusk in the Chinese market."

When the puppy was discovered, scientists from the Stockholm-based Centre for Palaeogenetics took a piece of bone to study its DNA.

"The first step was of course to send the sample to radio carbon dating to see how old it was and when we got the results back it turned out that it was roughly 18,000 years old," Love Dalen, professor of evolutionary genetics at the center, said in an online interview.

Further tests, however, left the scientists with more questions than answers - they could not definitively tell whether it was a dog or a wolf.

Dalen said scientists were about to do a third round of genome sequencing, which might solve the mystery.

Australian Associated Press

Original post:
18000-year-old puppy found in permafrost - The Canberra Times

Recommendation and review posted by Bethany Smith

Glenn Gaudette, William Smith Deans Professor of Biomedical Engineering at Worcester Polytechnic Institute (WPI), has been named a fellow of theNational Academy of Inventors(NAI), the organization announced today. Gaudette is the founding director of the WPI Myocardial Regeneration Lab, where he has pioneered the use of plants as scaffoldingfor heart regeneration.

The NAI Fellows Program highlights academic inventors who have demonstrated a spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development and the welfare of society. Election to NAI Fellow is the highest professional distinction accorded solely to academic inventors.

I am honored and humbled to be selected as a Fellow of the NAI. This prestigious recognition is a reflection of amazing collaborators, fantastic students, risk-taking funding organizations and a supportive family that I have been fortunate to benefit from, said Gaudette. Today, significant engineering and science advancements require a focus on creating value for society, work that flourishes in an open and collaborative environment like the one I enjoy at WPI.

As director of the Myocardial Regeneration Lab, Gaudette focuses broadly on cardiovascular regeneration techniques, but more specifically on developing better ways to deliver cells to damaged myocardium as well as better techniques to analyze cardiac mechanics. He has authored over 75 publications, including a co-edited book on cardiovascular regeneration, has four issued patents, and founded a company based on the technology developed in his laboratory. His research, which is supported by the National Institutes of Health and the National Science Foundation, aims to develop a treatment for the millions of Americans suffering from myocardial infarction and other cardiovascular diseases.

As a member of the NAI 2019 Fellows, Gaudette joins 168 educators and researchers representing 136 universities and governmental and nonprofit research institutes worldwide. Collectively, they hold over 3,500 issued U.S. patents. Among the 2019 Fellows are six recipients of the U.S. National Medal of Technology & Innovation or U.S. National Medal of Science and four Nobel Laureates, as well as recipients of other honors and distinctions. Their collective body of research covers a range of scientific disciplines including neurobehavioral sciences, horticulture, photonics and nanomedicine.

To date, NAI Fellows hold more than 41,500 issued U.S. patents, which have generated over 11,000 licensed technologies and companies, and created more than 36 million jobs. In addition, over $1.6 trillion in revenue has been generated based on NAI Fellow discoveries.

On April 10, 2020, the 2019 NAI Fellows will be inducted at the Heard Museum in Phoenix, Arizona as part of the Ninth Annual NAI Meeting. Laura A. Peter, Deputy Under Secretary of Commerce for Intellectual Property and Deputy Director of the United States Patent and Trademark Office (USPTO),will provide the keynote address for the induction ceremony. At the ceremony, Fellows will be formally inducted by Peter and NAI President Paul R. Sanberg in recognition of their outstanding achievements.

In addition to being named an NAI Fellow, Gaudette is a Fellow of the American Institute for Medical and Biological Engineering. His teams research usingspinach leavesas scaffolds for growing human heart cells has been featured by media outlets throughout the world, including the BBC, theWashington Post,and Time.com. The work was named one of the top medical breakthroughs of the year byBoston Magazineand was the seventh most popular story of 2017 inNational Geographic. He has also worked on a novel technology using fibrin sutures to deliver stem cells to targeted areas of the body to repair diseased or damaged tissue, including cardiac muscle damaged by a heart attack.Outside the lab, Gaudette teaches biomedical engineering design and innovation, biomechanics and physiology. He promotes the development of the entrepreneurial mindset in his students through support provided by the Kern Family Foundationand serves as the director of the Value Creation Initiative at WPI.In 2015, he was named Faculty Member of the Year by the Kern Entrepreneurial Engineering Network (KEEN).

Go here to read the rest:
Professor Recognized For Cardiac Regeneration Research - WPI News

Recommendation and review posted by Bethany Smith

A new study released today in STEM CELLS outlines how fat grafting - which previous studies have shown can reduce and even reverse fibrosis (scar tissue) buildup - also improves the range of motion of the affected limb. The study, conducted by researchers at Stanford University School of Medicine, was conducted on mice.

DURHAM, N.C., Dec. 3, 2019 /PRNewswire-PRWeb/ --A new study released today in STEM CELLS outlines how fat grafting which previous studies have shown can reduce and even reverse fibrosis (scar tissue) buildup also improves the range of motion of the affected limb. The study, conducted by researchers at Stanford University School of Medicine, was conducted on mice.

The tumor-destroying capabilities of radiation therapy can be a life saver for a person suffering from cancer. But it's a therapy that has several unwanted side effects, too, including causing substantial damage not just to cancerous cells, but any healthy tissue in its path. Over time, fibrosis builds up in the treated area which, in the case of an arm, shoulder, or leg, for example, can lead to painful contractures that significantly limit extensibility and negatively impact the person's quality of life.

The Stanford team irradiated the right hind legs of subject mice, which resulted in chronic fibrosis and limb contracture. Four weeks later, the irradiated limbs of one group of the mice were injected with fat enriched with stromal vascular cells (SVCs). These potent cells already naturally exist in fat, but supplementation of fat with additional SVCs enhances its regenerative capabilities. A second group was injected with fat only, a third group with saline and a fourth group received no injections, for comparison. The animals' ability to extend their limb was then measured at baseline and every two weeks for a 12-week period. At the end of the 12 weeks, the hind limb skin underwent histological analysis and biomechanical strength testing.

"Each animal showed significant reduction in its limb extension ability due to the radiation, but this was progressively rescued by fat grafting," reported corresponding author Derrick C. Wan, M.D., FACS. Fat grafting also reduced skin stiffness and reversed the radiation-induced histological changes in the skin.

"The greatest benefits were found in mice injected with fat enriched with SVCs," Dr. Wan added. "SVCs are easily obtained through liposuction and can be coaxed into different tissue types, where they can support neovascularization, replace cells and repair injured issue.

"Our study showed the ability of fat to improve mobility as well as vascularity and appearance," he continued. "We think this holds enormous clinical potential especially given that adipose tissue is abundant and can be easily collected from the patients themselves and underscores an attractive approach to address challenging soft tissue fibrosis in patients following radiation therapy."

Furthermore, said co-author and world-renowned breast reconstructive expert Arash Momeni, M.D., FACS, "Our observations are potentially translatable to a variety of challenging clinical scenarios. Being able to reverse radiation-induced effects holds promise to substantially improve clinical outcomes in implant-based as well as autologous breast reconstruction. The study findings are indeed encouraging as they could offer patients novel treatment modalities for debility clinical conditions.

"Excessive scarring is a challenging problem that is associated with a variety of clinical conditions, such as burn injuries, tendon lacerations, etc. The potential to improve outcomes based on treatment modalities derived from our research is indeed exciting," Dr. Momeni added.

"Skin and soft tissue scarring and fibrosis are well-established problems after radiation. The current study, showing that human fat grafting can normalize the collagen networks and improve tissue elasticity in immune deficient mice, provides molecular evidence for how fat grafting functions," said Dr. Jan Nolta, Editor-in-Chief of STEM CELLS. "The studies indicate that, with the appropriate regulatory approvals, autologous fat grafting could potentially also help human patients recover from radiation-induced tissue fibrosis."

The full article, "Fat grafting rescues radiation-induced joint contracture," can be accessed at https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/stem.3115.

Story continues

About the Journal: STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research. STEM CELLS is co-published by AlphaMed Press and Wiley.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. STEM CELLS (http://www.StemCells.com) is the world's first journal devoted to this fast paced field of research. THE ONCOLOGIST (http://www.TheOncologist.com) is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS TRANSLATIONAL MEDICINE (http://www.StemCellsTM.com) is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.

SOURCE STEM CELLS

Read more:
Fat grafting improves range of motion in limbs damaged by radiation therapy - Yahoo Finance

Recommendation and review posted by Bethany Smith

Novadip Biosciences to present data at 17th Annual Meeting of the International Federation for Adipose Therapeutics and Science

Mont-Saint Guibert, Belgium, 4 December, 2019: Novadip Biosciences (Novadip or the company), a clinical-stage biopharmaceutical company leveraging its unique tissue regeneration technology platform to generate multiple product candidates, announces that it is presenting data in a series of presentations at the 17th Annual Meeting of the International Federation for Adipose Therapeutics and Science (IFATS) taking place in Marseille, France, from 4-7 December 2019.

Dr Denis Dufrane, Chief Scientific Officer and co-founder, Novadip, commented: The findings that will be presented at IFATS highlight the capabilities of Novadips 3-dimensional, scaffold-free extracellular matrix (ECM) technology platform utilizing adipose-derived stem cells (ASCs) to generate product candidates to address critical size bone and skin reconstruction, as well as our manufacturing capabilities and expertise. We look forward to progressing our clinical programmes and generating further data in support of our unique platform as we look to address hard and soft tissue reconstruction for patients who have limited or no treatment options.

Novadip will deliver five oral presentations and one video presentation. Details of the presentations and short summaries are below.

Genetic stability assessment in bone tissue-engineered productsCline Pierard, oral presentation #8 (abstract 1395), 5 December 2019, 8:38 am CET

The presentation will discuss the different analytical approaches to predict the genetic behavior over the entirety of the manufacturing process for the companys product candidates for bone reconstruction.

A scaffold-free graft for large critical size bone defect: preclinical evidence to clinical proof of conceptSophie Veriter, video presentation #V5 (abstract 1363), 5 December 2019, 2:48 pm CET

The session will discuss how the scaffold-free 3D-graft (comprised of ASCs) plays a major role promoting ASCs engraftment and to induce osteogenesis in a fibrotic environment and promote bone fusion in a critical-sized bone defect.

The in vivo immunogenicity of a human 3D scaffold-free tissue engineered product for bone reconstruction: a xenogenic modelGatan Thirion, oral presentation #30 (abstract 1382), 5 December 2019, 4:30 pm CET

Detail will be provided on how the human scaffold-free 3D approach, in a xenogenic model, can elicit a specific anti-human immune response but can maintain the potential of in vivo osteogenicity.

An allogenic 3D scaffold-free tissue engineered product for deep thickness skin regeneration: in vitro development to in vivo proof of conceptSophie Veriter, oral presentation #88 (abstract 1317), 6 December 2019, 5:50 pm CET

The presentation will discuss how the scaffold-free approach with the allogenic 3D-graft (derived from ASCs) demonstrated safety and efficacy in a stringent xenogenic model of hyperglycemic and ischemic deep-thickness wound.

Allogenic 3D scaffold-free tissue engineered product for deep thickness skin regeneration: in vitro characterization and in vivo biocompatibilityValrie Lebrun, oral presentation #90 (abstract 1341), 6 December 2019, 6:06 pm CET

The presentation will provide an overview on how the allogenic scaffold-free 3D-graft improves ASC bioactivity for the angiogenesis and in vivo remodeling by the specific ECM-proteins of wound healing.

Monitoring of cell culture conditions and early prediction of the quality of an osteogenic cell-based medicinal productAnas Namur, oral presentation #136 (abstract 1392), 7 December 2019, 2:44 pm CET

The session will describe how cellular metabolism was studied throughout the companys manufacturing process to better understand the physiology of the proliferative and differentiated cells and subsequently develop predictive tests focused on critical attributes of the final product.

To view the full abstracts, please follow this link.

The full list of abstracts can be found here. Further information on IFATS is available here.

- Ends -

Notes to editors

Novadip Biosciences

Novadip Biosciences is a clinical stage biopharmaceutical company leveraging its unique 3D tissue regeneration technology platform to generate multiple product candidates to address hard and soft tissue reconstruction for patients who have limited or no treatment options. The companys proprietary 3M3 platform is a 3-dimensional, extracellular matrix that utilizes adipose-derived stem cells to deliver highly-specific growth factors and miRNA to mimic the physiology of natural healing and creates a range of products that address specific challenges in tissue regeneration. Novadips initial focus is on critical size bone reconstruction and its lead program is in development for a rare pediatric orthopedic disease. The company is also applying its 3M3 platform to develop truly novel off-the-shelf/allogeneic therapies to address more prevalent tissue defects. For more information, visit http://www.novadip.com .

For further information, please contact:

Novadip Biosciences

Jeff Abbey

Chief Executive Officer

+32 (10) 779 220

info@novadip.com

For media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Angela Gray

+44 (0) 20 3709 5700

novadip@consilium-comms.com

Read more from the original source:
Novadip Biosciences to present data at 17th Annual Meeting of the International Federation for Adipose Therapeutics and Science - GlobeNewswire

Recommendation and review posted by Bethany Smith

Dr Sister Ltd continues to offer effective skin treatments to both men and women, and they have been doing this for over 45 years now. Doctor Sister provides a comprehensive portfolio of treatments while at the same time delivering natural-looking, regenerative and enhancing results for the face and body. They are big believers in helping slow down the ageing process for each client, as of course, they are unable to stop time for you.

At Dr Sister Ltd, you can be treated by a professional doctor that trains other practitioners. Dr Sisterhimself has introduced over ten ground-breaking treatments to the UK market, along with eight published books, many articles in international peer reviews medical journals and general press, as well as being one of UKs and Europes leading lecturer and trainer in the field of Aesthetic Medicine.

The treatments offered by Dr Sister Ltd are non-invasive so there is no surgery and no downtime. Some of the skin treatments on offer at Dr Sister Ltd include the following; mini face lift, non-surgical face lift, vampire facial, PRP treatment and PRP injection. That is not an exhaustive list and he is also a renowned hormonal expert.

Dr. Sister has perfected safe, effective, natural-looking treatments, which has made him a worldwide expert and teacher in regenerative and innovative procedures such as Dracula PRP, Mint Lift including the new Stem Cell Facelift.

The PRP treatment (Dr. Sister has his own superior trademarked version called Dracula Therapy) may be unfamiliar to some clients. Dr Sister explains the procedure in great detail on their site. APRP treatment is a powerful anti-ageing treatment that involves using your blood as an injectable treatment (PRP Injection). Dr Daniel Sister was the first to introduce the treatment into the UK, and now he calls it Dracula Therapy.

With the Dracula Therapy or vampire facial, you will notice results within 3-4 weeks, and often only one PRP injection is required. However, the treatment may need to be repeated every 2-6 months because of the on-going ageing process.

The PRP injections generally appeal to patients looking for a more natural approach to facial rejuvenation, which is the rejuvenation process of using their cells. This treatment does not use synthetic fillers or animal products and has no risks or side effects.

At Dr Sister Ltd, they are well known for their aesthetic treatments, in particular, the MINT lift and Dr Sister is the training partner for the MINT lift. It is a PDO thread lift that offers exceptional results. Dr. Sister has been particularly impressed by the results as it provides an immediate and obvious lift, which many of his patients are looking for.

Dr Sister Ltd also mentions that local anaesthetic is used making the procedure pain free, and patients generally return to work and usual activities the following day. There are many benefits such as soft tissue lifting, instant lift, results lasting around 18 months.

If you would like to find out more about the treatments on offer at Dr Sister Ltd, there are many ways to get in touch. You can email press@drdanielsister.com your query, and they will get back to you as soon as possible, or you can go online to their website at https://drdanielsister.com. On their site, you will find all the information about the top treatments, fees, testimonials, and Dr Sister Ltd.

Source:https://thenewsfront.com/dr-sister-ltd-offers-effective-skin-treatments-to-both-men-and-women/

Link:
Dr Sister Ltd Offers Effective Skin Treatments to Both Men and Women - The News Front

Recommendation and review posted by Bethany Smith

The healthcare industry has been focusing on excessive research and development in the last couple of decades to ensure that the need to address issues related to the availability of drugs and treatments for certain chronic diseases is effectively met. Healthcare researchers and scientists at the Li Ka Shing Faculty of Medicine of the Hong Kong University have successfully demonstrated the utilization of human induced pluripotent stem cells or hiPSCs from the skin cells of the patient for testing therapeutic drugs.

The success of this research suggests that scientists have crossed one more hurdle towards using stem cells in precision medicine for the treatment of patients suffering from sporadic hereditary diseases. iPSCs are the new generation approach towards the prevention and treatment of diseases that takes into account patients on an individual basis considering their genetic makeup, lifestyle, and environment. Along with the capacity to transform into different body cell types and same genetic composition of the donors, hiPSCs have surfaced as a promising cell source to screen and test drugs.

In the present research, hiPSC was synthesized from patients suffering from a rare form of hereditary cardiomyopathy owing to the mutations in Lamin A/C related cardiomyopathy in their distinct families. The affected individuals suffer from sudden death, stroke, and heart failure at a very young age. As on date, there is no exact treatment available for this condition. This team in Hong Kong tested a drug named PTC124 to suppress specific genetic mutations in other genetic diseases into the iPSC transformed heart muscle cells. While this technology is being considered as a breakthrough in clinical stem cell research, the team at Hong Kong University is collaborating with drug companies regarding its clinical application.

The unique properties of iPS cells provides extensive potential to several biopharmaceutical applications. iPSCs are also used in toxicology testing, high throughput, disease modeling, and target identification. This type of stem cell has the potential to transform drug discovery by offering physiologically relevant cells for tool discovery, compound identification, and target validation. A new report by Persistence Market Research (PMR) states that the globalinduced pluripotent stem or iPS cell marketis expected to witness a strong CAGR of 7.0% from 2018 to 2026. In 2017, the market was worth US$ 1,254.0 Mn and is expected to reach US$ 2,299.5 Mn by the end of the forecast period in 2026.

Customization to be the Key Focus of Market Players

Due to the evolving needs of the research community, the demand for specialized cell lines have increased to a certain point where most vendors offering these products cannot depend solely on sales from catalog products. The quality of the products and lead time can determine the choices while requesting custom solutions at the same time. Companies usually focus on establishing a strong distribution network for enabling products to reach customers from the manufacturing units in a short time period.

Entry of Multiple Small Players to be Witnessed in the Coming Years

Several leading players have their presence in the global market; however, many specialized products and services are provided by small and regional vendors. By targeting their marketing strategies towards research institutes and small biotechnology companies, these new players have swiftly established their presence in the market.

Read more here:
Induced Pluripotent Stem Cells Market To Register High Revenue Growthat 7% CAGR Throughout 2018 to 2026 - Kentucky Reports

Recommendation and review posted by Bethany Smith

TMRR, in its recent market report, suggests that the Stem Cell Therapy market report is set to exceed US$ xx Mn/Bn by 2029. The report finds that the Stem Cell Therapy market registered ~US$ xx Mn/Bn in 2018 and is spectated to grow at a healthy CAGR over the foreseeable period. This Stem Cell Therapy market study considers 2018 as the base year, 2019 as the estimated year, and 2019 2029 as the forecast timeframe.

The Stem Cell Therapy market research focuses on the market structure and various factors (positive and negative) affecting the growth of the market. The study encloses a precise evaluation of the Stem Cell Therapy market, including growth rate, current scenario, and volume inflation prospects, on the basis of DROT and Porters Five Forces analyses. In addition, the Stem Cell Therapy market study provides reliable and authentic projections regarding the technical jargon.

Important regions covered in the Stem Cell Therapy market research include Region 1 (Country 1, country 2), Region 2 (Country 1, country 2), Region 3 (Country 1, country 2) and Region 4 (Country 1, country 2).

Exclusive offer!!! Purchase reports at a discounted price!!!

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1787&source=atm

The Stem Cell Therapy market study answers critical questions including:

The content of the Stem Cell Therapy market report includes the following insights:

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1787&source=atm

On the basis of component, the global Stem Cell Therapy market report covers the following segments:

Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

All the players running in the global Stem Cell Therapy market are elaborated thoroughly in the Stem Cell Therapy market report on the basis of R&D developments, distribution channels, industrial penetration, manufacturing processes, and revenue. In addition, the report examines, legal policies, and comparative analysis between the leading and emerging Stem Cell Therapy market players.

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=1787&source=atm

Why choose TMRR?

The rest is here:
Sales of the Stem Cell Therapy Market to Anticipated to Exceed US$ XX by 2017 - 2025 - Markets Gazette 24

Recommendation and review posted by Bethany Smith

Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2019 Industry Research Report gives vital information then analytical data of Autologous Stem Cell and Non-Stem Cell Based Therapies Market Size, Share, Growth, Key Players then forecast. Furthermore it provides development trends and marketing channels analysis. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. This report also presents product specification, manufacturing process, and product cost structure.

You can get a sample copy of this report at https://www.orianresearch.com/request-sample/1380754

Autologous stem-cell transplantation is autologous transplantation of stem cells in which stem cells are removed from an individual, stored, and later given back to that same individual.

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market was estimated to be valued at USD XX million in 2018 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2019 to 2026. The increase in chronic diseases is one of the chief factors supplementing the market growth. Conversely, the lack of awareness regarding the potential benefits of stem cells might hamper the market growth.

The global autologous stem cell and non-stem cell based therapies market is segmented on the basis of technology and region. Based on technology the market is segmented into neurodegenerative diseases, cardiovascular diseases, cancer and autoimmune diseases, skin transplantation and infectious disease. Based on region, it is studied across North America Europe, Asia-Pacific, South America and Middle East and Africa.

Inquire more or share questions if any before the purchase on this https://www.orianresearch.com/enquiry-before-buying/1380754 The key players profiled in the market include:* Antria* Bioheart* Brainstorm Cell Therapeutics* Cytori* Dendreon Corporation* Fibrocell* Genesis Biopharma* Georgia Health Sciences University* Neostem* Opexa Therapeutics

The report offers the market growth rate, size, and forecasts at the global level in addition as for the geographic areas: Latin America, Europe, Asia Pacific, North America, and Middle East & Africa. Also it analyses, roadways and provides the global market size of the main players in each region. Moreover, the report provides knowledge of the leading market players within the Autologous Stem Cell and Non-Stem Cell Based Therapies Market. The industry changing factors for the market segments are explored in this report. This analysis report covers the growth factors of the worldwide market based on end-users.

Purchase Directly @ https://www.orianresearch.com/checkout/1380754

Key Benefits of the Report:

On the basis of technology, the market is split into:* Neurodegenerative Diseases* Cardiovascular Diseases* Cancer and Autoimmune Diseases* Skin Transplantation* Infectious Disease

Table of Contents:

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Industry Market Research Report

1 Autologous Stem Cell and Non-Stem Cell Based Therapies Introduction and Market Overview

2 Industry Chain Analysis

3 Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market, by Type

4 Autologous Stem Cell and Non-Stem Cell Based Therapies Market, by Application

5 Global Autologous Stem Cell and Non-Stem Cell Based Therapies Production, Value ($) by Region (2014-2019)

6 Global Autologous Stem Cell and Non-Stem Cell Based Therapies Production, Consumption, Export, Import by Regions (2014-2019)

7 Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Status and SWOT Analysis by Regions

8 Competitive Landscape

9 Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis and Forecast by Type and Application

10 Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis and Forecast by Region

11 New Project Feasibility Analysis

12 Research Finding and Conclusion

13 Appendix

Customization Service of the Report:-

Orian Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us:

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us

Ruwin Mendez

President Global Sales & Partner Relations

Orian Research Consultants

US: +1 (415) 830-3727 | UK: +44 020 8144-71-27

Email: [emailprotected]

Website: http://www.orianresearch.com/

See the original post here:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2019 by Technology (Neurodegenerative Diseases, Cardiovascular Diseases, Cancer and...

Recommendation and review posted by Bethany Smith

Within days of giving birth, a womans estrogen and progesterone levels quickly drop, leading to chemical changes in the brain that might give rise to shifts in mood. In fact, as many as three in four mothers experience symptoms of depression soon after childbirth. But for one in nine mothers, those symptoms result in a more serious, longer-lasting, and potentially life-threatening condition known as postpartum depression. The disorder, which manifests as a significant change in mood within hours to weeks of giving birth, is the most common complication of pregnancy. Currently, the depression drugs used to treat it take weeks to months to kick intime that new mothers (and their infants) cant afford. Zulresso is the first FDA-approved medication designed to tackle postpartum depression, and it does so at speed. The drug is a synthetic form of allopregnanolone, a hormone that dampens neural activity and eases depression symptoms when estrogen and progesterone levels dip. In double-blind control studies run by the creators at Sage Therapeutics, Zulresso worked within 60 hours. Right now, the drug is administered via a 60-hour intravenous infusion (common among new medicines), but alternative treatments, including a pill form, are currently in clinical trials.

Follow this link:
100 greatest innovations of 2019: Best of What's New - Popular Science

Recommendation and review posted by Bethany Smith

This is a guest contribution for The Economists Open Future initiative, which aims to foster a global conversation on the challenges of the 21st century. More Open Future articles are at Economist.com/openfuture

* * *

The day I knew I should quit my job answering phones at the transgender health-care clinic in California was the day a caller (lets use the name Betty) threatened her in-home caretaker with a knife during the call. As the caretaker begged our clinics nurse to track down Bettys doctor and tell him that Betty was having a psychotic episode, Betty stood between her and the apartments front door with a kitchen knife. Betty had poorly controlled paranoid schizophrenia, and often called the clinic agitated, alternately whispering and screaming about government agents stalking her. Betty was also a trans woman whom most people regarded as male, the sex of her birth.

Upgrade your inbox and get our Daily Dispatch and Editor's Picks.

The clinic followed the informed-consent protocol: its mission was to provide transgender patients who otherwise lacked access to health care with injections, skin patches and pills of feminising or masculinising hormones without having to pass through a series of requirements and assessmentsknown as gatekeepingthat restricted access in the past.

In medicine broadly, informed-consent refers to the ethical requirement that a clinician administering a treatment communicate to the patient the anticipated risks and benefits, as well as reasonable alternatives to the treatment. Yet for transition medicine in America, informed-consent programmes do not require clinical documentation, beyond patient reports, of the patients gender dysphoria over time (ie, a feeling of mismatch between ones biological sex and gender identity) and readiness for medical interventions.

Gatekeeping horror stories are notorious in the transgender community. In the past it was not unusual for a trans person to be told by doctors and psychologists they would not be referred for hormones because they were not visually appealing as their preferred gender, werent interested in dating the opposite gender, or had unresolved mental-health problems (some of which are predictable responses to experiencing transphobia, such as anxiety and depression).

It was not unusual for a trans person to be told they would not be referred for hormones because they were not visually appealing

Pioneering LGBT health centres across America developed informed-consent protocols for hormone treatment in a well-intentioned effort to imbue the experience of pursuing hormone treatment with dignity for patients. But as informed-consent protocols have become the norm rather than the exception, we may be shunting transgender people in America into a parallel medical systemone in which patients bargain away careful assessment and education for greater autonomy and shortened timelines to access medical treatments.

At my clinic, we were informed-consent true-believers. We didnt badger you with questions; as long as you were 18, even if you had no way to pay the clinics fees, you would get your hormones. You had to sign forms stating that you understood that although hormone-replacement therapy (HRT) benefits many trans people suffering from gender dysphoria, the health risks are largely unknown. Starting hormones could have negative consequences for your mental well-being, social functioning and even the intensity of your gender dysphoria (many people find that their distress about a body part like their breasts will only increase when the effects of testosterone appear, such as facial hair).

Also, people were informed that they were waiving the mental-health screening recommended by the World Professional Association for Transgender Health. Its standard of care recommends that patients seeking HRT be screened for schizotypal disorders, autism-spectrum disorders, personality disorders, dissociative disorders, post-traumatic stress disorders and more.

In the case of Betty, I felt that the clinic where I worked wasnt sufficiently concerned whether her mental disorder created delusions that often controlled her life, or meant she was so cognitively disabled that transition predictably left her more isolated and chronically stressed than before she started HRT. The medical staffs attitude towards Betty and many of the other patients who were receiving hormones while managing (or failing to manage) severe mental illness was a profound lack of interest about whether one affected the other.

We were informed-consent true-believers. We didnt badger you with questions; as long as you were 18, you would get your hormones.

In fact, most of us worked there because we rejected the idea that a strongly felt internal sense of gender could be a symptom of mental illness. That shared, ideological foundation meant it was verboten for the staff to consider whether the HRT might be exacerbating Bettys schizophrenic symptoms or making it harder for her to build the basic social relationships that provide the support and positive feedback that is so necessary for mental health. If the HRT did not actually assist Betty in presenting as a woman or improve her functioningand it seemed to be doing neitherwe considered affirming her identity more important than those conventional measures of the treatments effectiveness.

The most radical and liberatory action we could take was to affirm Bettys identity. If we were the one and only place she visited in her day where she was referred to using her chosen pronouns, we considered it paramount we gave her that experience. This commitment to affirming identity through correct pronouns and easy HRT was our reason for being. But strangely, by fulfilling our commitment to affirming felt identity, we seemed to be off the hook for questioning whether we were doing all we could to avoid harming her.

I quit the clinic in 2014, and in 2016 I spoke to the lawyer of a patient suing that same clinic. This patient also pursued HRT while experiencing intense delusional symptomsit was 2012 and he thought the world was ending. The clinic, affirming as ever, recommended and provided the referral letters for him to have an orchiectomy, a removal of his testicles, which he underwent. When his delusional symptoms eventually abated he detransitioned, coming to an uneasy peace being, and presenting as, male.

I know him because we are both detransitioned people. I was also convinced that I was a trans personas a result of misunderstanding a persistent sense that my body felt unreal, a common dissociative symptom following traumaand received HRT at this same clinic, taking testosterone for nine months. For the past five years Ive been a part of a growing community of detransitioned people who are speaking out about questionable norms and practices in transgender medicine.

The clinic, affirming as ever, provided the referral letters for him to have an orchiectomy, a removal of his testicles

When I first detransitioned, my community consisted of online groups of fewer than 100 women. Five years later the detransition discussion-forum on the popular site Reddit has just hit 7,000 people of both sexes. I know detransitioned people who later discovered they had autism-spectrum disorders, detransitioned people who came to recognise that they were experiencing traumatic dissociation, even detransitioned people who had such severe dissociation that they had multiple alters (ie, multiple identities) while being treated with hormones and surgeries.

Our stories, if taken seriously, could help improve the state of transgender health careparticularly at informed-consent clinics, which are becoming the norm at American colleges, LGBT health centres and recently many Planned Parenthoods. Instead we are ignored, compared to ex-gay Christians or treated as political footballs. (I was particularly disheartened when Ryan Anderson, a fellow at the Heritage Foundation, a conservative think-tank, used my and other detransitioners stories in his book that was critical of LGBT and feminist issues, When Harry Became Sally.)

That is because the burgeoning orthodoxy on the left is that detransition is so rare that only transphobes care about it. If you draw attention to the stories of transition gone wrong, the thinking goes, there will be less public support for transition and for transgender people themselves. For academic researchers and journalists, telling our stories is a fast track to being labelled a transphobe. This has profound consequences for what we know about the medical paths that leads to detransition.

In fact, we have no idea how prevalent detransition is in America. The most widely used estimate, that 2.2% of people who transition later detransition, comes from a study in a completely different place (Sweden) and time (1960-2010), when gatekeeping was much stricter. Moreover, that study defined a detransitioner as someone who had changed their name and gender legally (an arduous process in Sweden at the time) and then had the motivation and money to go through the name change process in reverse, a standard so strict that I wouldnt be counted, and nor would 90% of the detransitioners I know.

If you draw attention to the stories of transition gone wrong, the thinking goes, there will be less public support for transgender people

This passionate but misguided argumentthat detransition is extremely rare, thus any research into it is harmful and motivated by transphobiahas led to outright censorship. In 2017 Bath Spa University in Britain shot down a research proposal that sought simply to collect stories from detransitioners. The same year the Philadelphia Trans Health Conference, a major annual gathering of the transgender health community, abruptly cancelled two previously approved panels that I had helped organise on detransition and alternative methods of managing gender dysphoria, because of the level of heated conversation and controversy. These were just two out of nearly 200 sessions.

As a result, the subject of detransitioners health-care experiences remains virtually untouched by academic researchers. This shows in the clumsy approaches of those few researchers willing to engage the subject. For example, a poster presented this summer at the European Professional Association of Transgender Health conference purported to show a very low rate of detransition and regret (0.47%) at an NHS clinic in London. The poster bounced all over social media, cited as proof that detransition is indeed exceptionally rare.

But that estimate was generated by combing through case files for patients who returned to the clinic to inform staff of their detransition or regret. The thing is, though, detransitioners almost never do this. This is widely known within the communitywhy would you go back to a clinic or to a doctor who, in your view, helped you hurt yourself?

Apart from the few who sue their doctors and therapists, detransitioners tend simply to disappear from a clinics view, despite often having urgent needs for continued medical treatment and therapy. I have heard of only three detransitioners who went back to talk to the clinicians who had assisted them in transitioning. (The experience of one who did just that convinced me that I probably never will.) Nor do they tend to go to other clinics for follow-on care: they simply become invisible.

The majority of the studies supporting the conclusion that medical transition yields positive outcomesand there are manyfollowed patients in highly structured clinical programmes that provided comprehensive assessments. But when I searched last February for programmes that met that careful standard in America, I wasnt able to find one. No one knows whether informed-consent protocols will yield the same success rate, but the stories Ive heard during the past five years make me profoundly sceptical.

In a comprehensive examination of peer-reviewed articles on medical-transition between 1991 and 2017 by researchers art Cornell University, called What We Know, there have been no studies tracking a cohort of patients at an informed-consent clinic over time to investigate the outcomes that their protocol produces. Moreover, there have been no studies on what percentage of clinics in America follow the standard of care recommended by the World Professional Association for Transgender Health versus their own informed-consent protocols.

From the point of view of clinics, they would respond to the criticisms by noting that informed-consent clinics often serve a poor and transient population, which presents challenges to following up with patients. Another difficulty is that transgender medicine is a relatively new field serving a small minority of the population, necessarily limiting funding and opportunities for research. As to whether informed-consent policies have the effect of leading people to medical interventions too soon, they would argue that the people who end up feeling ill-served by the high level of patient autonomy will always be a small minority.

Yet this does not obviate the need for better practices. I dont want informed-consent clinics shuttered. I want them to do the tasks normally associated with medical care. This includes giving patients access to differential diagnosis (distinguishing between conditions that share similar symptoms) and follow-up research so that providers can improve the care they offer.

There is a responsible path between making transgender people jump through hoops and allowing people experiencing psychosis to have their testicles removed

For example, ensuring that low-cost psychology referrals are offered to all patients seeking informed-consent care could increase voluntary participation in comprehensive evaluations. Ensuring that staff are trained to identify patients showing signs of certain severe disorders, and to provide psychological evaluations when appropriate, could help prevent outcomes like Bettys.

Even ensuring that all clinics have counselling referrals on hand would be a step in the right direction. Although I received a prescription for hormones by my second visit, many patients sat on the waiting list for counselling from the same clinics social workers for more than five months and when I requested an outside referral, I was told to google the phone number of a local counselling internship site.

There is a responsible middle path between making transgender people jump through hoops to access needed medical care and allowing people experiencing psychosis and delusions to have their testicles removed. Until gender care providers accept their ethical responsibility to find that path, the American medical system continues to serve this community of people poorlybut this time, this neglect is designed and perpetrated by allies under the banner of transgender rights.

_________________

Carey Callahan is a family therapist and board member of the Gender Care Consumer Advocacy Network, a non-profit group that advocates for the rights and welfare of consumers of gender care services.

Go here to read the rest:
Gender identity is hard but jumping to medical solutions is worse - The Economist

Recommendation and review posted by Bethany Smith

Mitchell Levine is the new director of the Dental Sleep Medicine Clinic at the University of Tennessee Health Science Center's College of Dentistry.(Photo: Natalie Brewer / UTHSC)

Mitchell Levine wants the clinic he leads to help Shelby County Schools "educate and inform" faculty on identifyingchildren with sleep apnea, which can hinder brain development.

I think faculty in particular may just not be aware, said Levine, director of the Dental Sleep Medicine Clinic at the University of Tennessee Health Science Centers College of Dentistry. They think the child is just not performing well or acting out. They dont always associate it with sleep problems.

Sleep apnea isa condition in which the airway is blocked during sleep, obstructing oxygen intake. It can increase the risk of heart disease and other disorders, according to the National Heart, Lung,and Blood Institute.

For adults, using continuous positive air pressure (CPAP) machines manages the problem. Getting children desensitized and willing to use a CPAP is "no doubt" more difficult, Levine said, and untreated sleep apnea can hinder their neurological, psychosocial and decision-making development, according to UTHSC.

Dental assistant Abby Ridings (left) and fourth-year dental student Carlton Leding clean 11-year-old Tierra Moore's teeth during a visit to the University of Tennessee Health Science Center College of Dentistry on National Give Kids A Smile Day on Thursday, Feb. 2, 2017.(Photo: Yalonda M. James/USA TODAY NETWORK - Tennessee)

That manifests itself in shortcomings at school, which could spiral into challenges beyond the classroom, said Levine, who became director Aug. 1.

Kids who are not being managed well (with sleep breathing) puts them at a disadvantage as they continue to age, he said.

Tackling adult sleep apnea is about managing the problem, unless there is a willingness to undergo major surgery, Levine said. CPAP or oral devices that fit like retainers and keep the airway openare typical treatment options, per UTHSC.

For pediatric sleep apnea, Levine said treating it isabout redirecting the growth processes of the jaw to improve the effectiveness of the airway during sleep.Jaw positioning and enlarged tonsils and adenoids are connected to sleep apnea in children, Levine said.

When snoring becomes a regular occurrence it could be a more serious condition called obstructive sleep apnea. Many use a CPAP mask to help get past this condition.(Photo: nicolesy, Getty Images/iStockphoto)

I think what were realizing is in childrens sleep problems and adults' sleep problems is the manifestations of them seem to be a bit different, he said.

Repositioning the jaw is effective when the child is 8 or 9 years old and growing fast. Before that age range, oral devices come in handy, because structural changes to growth aren't as effective at 5 or 6 years old, Levine said.

An oral device may be all that's needed for a young child with sleep apnea. Over time, natural growth may rid the child of the structural cause, Levine said.

We had parents that would talk about kids not having nightmares anymore or sleepwalking, doing better at school and moving into their own bedrooms again, Levine said of helping children with sleep apnea. There is a unique opportunity on the pediatric side.

Levine hopes UTHSC and the clinic he heads willfind a role in the community beyond custom-fitted oral devices and orthodontic treatments.

Addressing children with sleep-breathing problemsis a key example of that, being a new focus for the clinic. Levine said he has a different perspective than previous leadership due to his experience treating children and addressing orthodontic development.

A dental implant designed by Dr. Ryan Robinson, a dentist at Pike Creek Dental, to treat patients diagnosed with sleep apnea.(Photo: Jennifer Corbett, The News Journal)

If Shelby County Schools faculty can identify children with pediatric sleep apnea, they can direct them to resources that will address the disease, Levine said. SCS and UTHSC have a general partnership already, but a more direct, sleep apnea-focused effort would boost awareness regarding the issue.

Other factors can negatively affect sleep for young people outside of trouble breathing, like using electronics before bed, Levine pointed out. Blue light emitted from smartphones, tablets and other devices competes with melatonin, a natural hormone connected to the onset of sleep.

Early school start times are also a big issue, particularly among high school students with delayed sleep patterns, homework and after-school activities to manage, Levine said. Those students can be at risk for drowsy driving.

A whole education process needs to be introduced, he said.

Max Garland covers FedEx, logistics and health care for The Commercial Appeal. Reach him at max.garland@commercialappeal.com or 901-529-2651 and on Twitter @MaxGarlandTypes.

Read or Share this story: https://www.commercialappeal.com/story/news/2019/12/03/child-sleep-apnea-uthsc-dental-sleep-medicine-clinic-mitchell-levine/4299784002/

See the rest here:
Child sleep apnea: Here's why UTHSC clinic director wants to team up with Shelby County Schools - Commercial Appeal

Recommendation and review posted by Bethany Smith

with Ali Aminian, MD, and Caroline Apovian, MD

For those of you who have type 2 diabetes with obesity or have a family member that does, one of the best ways to reduce common health risks such as heart disease and stroke is by having gastric bypass surgery.1

The reason for this seems to be that metabolic surgeryany procedure that changes the function and structure of the stomach or small intestinesupports weight loss, leading to improvements in glucose control and insulin sensitivity; and, ultimately diminishes the complications associated with diabetes. Still, how can you be sure that surgery is the right way to go?

Cleveland Clinic researchers have developed a risk assessment tool to give you a sense of your health risks for diabetes complications in the decade ahead if you do or don't have bariatric surgery. Photo: fstop123 @ iStock

Recognizing that surgery is a daunting step for some and represents too much uncertainty for others, a web-based risk assessment calculator was created by a team of investigators at the Cleveland Clinic in Ohio to help you to determine if bariatric surgery will favorably improve your long-term health.2,3 The results can be shared with your health provider as a starting off point in discussing a disease management plan now and going forward.

This predictive tool is intended to guide you and your doctor to understand the long-term medical risks associated with type 2 diabetes (T2D) and obesity, and to consider the benefits you might gain from having this surgery,2 says Ali Aminian, MD, a bariatric surgeon at the Cleveland Clinic who presented the research supporting development of this tool at a session during ObesityWeek 2019, in Las Vegas, Nevada.

Dr. Aminian outlined the development of the risk calculator. He and his team evaluated the experiences of 13,722 patients with both diabetes and obesitycomparing patients who underwent bariatric surgery as compared to closely matched individuals who were eligible for surgery but chose to continue with their standard medical treatment.2

After following these patients, the individuals who elected to have surgery proved to have a lower risk for every one of the five common complications associated with diabetes. These included: heart disease, stroke, heart failure, kidney disease, and death from all causes.2

Across the board, following these gastric procedures, individuals had a lower risk of every diabetes-related risk. Unfortunately, fewer than 1% of the patients who were eligible for bariatric surgery have it,3 he says.

The researchers than gathered relevant data from the medical records of nearly 290,000 patients with obesity who were being treated for type 2 diabetes in the Cleveland Clinic Health System from 2004 to 2007.Health measures including age, sex, body mass index (BMI), diabetes-related complications, and medications taken were combined to determine patient-specific risks. The researchers also incorporated levels of hemoglobin A1c, blood pressure, and blood cholesterol levels.3

The data supporting the impact of weight-loss surgery on complications of type 2 diabetes, such as stroke and heart disease as well as kidney disease, was published in the Journal of the American Medical Association.2 The results support use of the risk calculator since the data indicated that patients who had metabolic surgery were 39% less likely to experience conditions such as heart disease, stroke, or diabetic kidney disease and 41% were less likely to die from any cause.2,3

When used by an individual, the risk assessment tool can help give both patients and providers a 10-year disease probability of developing the life-threatening complications related to diabetes if the current path is continued, as well as a comparison should you choose to undergo bariatric surgery.

How Effective Is the Gastric Bypass Risk Assessment Tool? As the Individualized Diabetes Complications (IDC) risk calculator was only just released, there hadnt been enough time to gather feedback yet, Dr. Aminian tells EndocrineWeb. However, he has already heard from several enodcrinologists, cardiologists, and primary care providers that they intend to use the calculator in their practices.

According to Caroline Apovian, MD, of Boston University School of Medicine, the reason for greater disease complications stems from a failure of primary care physicians and endocrinologists to recommend more eligible patients discuss their status with a bariatric surgeon. This risk calculator will help not just patients but also providers to realize the benefits of gastric surgery beyond weight loss, and to recognize the risks of not choosing to have surgery, she says.

While there isnt currently a way to determine which bariatric procedure would be best for each individual, Dr. Apovian tells EndocrineWeb, there are studies that indicate that the Roux-en-Y Gastric Bypass offers the best effect on hormone levels.4-6Dr. Aminian acknowledges that despite the limitations of the risk assessment tool as it doesnt include information on family history of heart disease or length of time with type 2 diabeteswhich would be helpful in addressing patient risk, the results derived by the IDC assessment are still valid.2,3

These gastric procedures are very powerful and safe methods for treating individuals with both obesity and type 2 diabetes, says Dr. Aminian. Having surgery can provide significant weight loss, improve diabetes, cholesterol levels, delivering a survival benefit as well as improved quality of life. Even though treating these patients with bariatric surgery is known to be beneficial, a lack of access to trained surgeons and the stigma associated with any method of weight loss besides diet and exercise, has made this option less desirable, he says.

Dr. Apovian has already made use of the ICD assessment tool in her practice It adds a spotlight that can help patients to better grasp the benefits to surgery.

In another presentation delivered at ObesityWeek 2019 in Las Vegas, Nevada, Oliver Varban, MD, associate professor of surgery including bariatric procedures in the University of Michigan Health System in Ann Arbor, presented data supporting the value of sleeve gastrectomy for individuals who have mild obesity (ie, body mass index [BMI] < 35 kg/m2).7 In this study of more than 45,000 patients, achieving a normal BMI occurring more often in patients with a starting BMI below 35 than above who also voiced greater satisfaction with the procedure.

In a press statement, Dr. Varban said: We hope the study encourages more patients to consider weight loss surgery earlier in their disease and for more health insurers to recognize the benefits of lowering the current BMI-threshold.

Indeed, it is most constructive for providers to introduce patients to this surgical assessment tool to help illuminate the risks individuals likely face in avoiding bariatric surgery, says Dr. Apovian. She anticipates that providers and patients might use the ICD tool together in an office setting when considering the need for treatment to improve outcomes and better manage type 2 diabetes with obesity.

Both physicians and patients still fail to treat obesity as a disease, says Dr. Apovian, raising a long-held observation. Too many doctors still view obesity as a matter of willpower and self-control, expecting patients alone to carry full responsiblity for losing weight. There is need for the medical community to acknowledge that obesity is a malfunction of metabolic pathways driving hunger and satiety talk between the gut and the brain.

Any educational tool that offers to dispel this old way of thinking is very welcome, says Dr. Apovian, as we need to help change attitudes so obesity can be approached as disease in need of medical intervention.

In the future, having more information included in the tool on who will develop heart disease on a genetic level could help patients and providers better target particular treatments to specific people.

The assessment algorithm doesnt allow for influences that may change the results based on demographic information such as race and ethnicity.2 Dr. Apovian has studied the impacts of surgery on different populations, and recently published data that showed that African American and Latino populations dont respond as well as Caucasians to metabolic surgery and are more likely to relapse into diabetes.4

Knowing the reasons for variability in outcomes based on racial differences could assure a more accurate and wider use of the ICD assessment tool but such developments still need more time in the academic incubator.2

More data on the type of surgery and outcomes across subpopulations would be good, says Dr. Apovian, particularly as sleeve gastrectomy produces a different impact on hormones related to satiety then the Roux-en-Y gastric procedure. We are starting to see conversions to Roux-en-Y after failed sleeve surgeries, she says.

As for the ICD tool, Id love to see all practitioners using this in their practices, says Dr. Apovian. It introduces sound numbers to the conversation with patients, and if that helps doctors convert more patients to opt in to surgery, then that will be great.

The Cleveland Clinic research received a research grant from Medtronic.

Last updated on 12/03/2019

Big Breakfast Beats Traditional 6-Meal Diabetes Diet

Continue reading here:
Web-based Tool to Help Assess Diabetes Outcomes With and Without Surgery - EndocrineWeb

Recommendation and review posted by Bethany Smith

Yeast isn't just found in bread it can also be found in everybodys genitals. Everyone has it, but it only causes an issue when it becomes out of balance with your bodys natural pH.

Vaginal candidiasis, or yeast infection, is a fungal infection that causes irritation, discharge and intense itchiness of the vagina and the vulva. This is NOT considered an STI. Theyre super common, and affect three-fourths of vagina owners at least once in their lifetime. Many people experience at least two episodes. There are over-the-counter medications that can treat them; however, you should always go to your doctor first, and if you experience recurrent ones, then you should talk to your doctor about different treatments and treatment plans.

For those with a penis, the yeast infection is referred to as candidal (or candida) balanitis. It affects the head of the penis mostly, but can also affect foreskin and the shaft depending on the intensity. For symptoms, you should usually look for burning or itching around the head (especially after having penetrative sex), redness, swelling, small bumps that may contain pus and pain during urination or sex. If you have a foreskin, you may also have difficulty cleaning or moving the foreskin. Unlike with vaginal yeast infections, penile yeast infections are usually acquired through sexual intercourse, but are generally easily treated. Additionally, you may acquire a yeast infection through skin problems or taking certain kinds of antibiotics (which can cause imbalance for the bodys natural genital pH).

You might have a yeast infection in your vagina if you notice these symptoms: Itching and irritation, burning during sex or urination, redness and swelling of the vulva, pain and soreness, a vaginal rash, thick, white, cottage cheese-like discharge or very watery discharge. All peoples discharge is different however. Always ask your doctor about sudden changes in discharge.

Yeast infections are caused by an imbalance in the natural bacteria and strains of yeast inside the vagina. It becomes an infection when the yeast becomes more present than the bacteria that normally keeps it in check. This imbalance can be caused by a number of things, including antibiotic use, which causes an imbalance in the natural vaginal flora, pregnancy, uncontrolled diabetes, an impaired immune system or taking oral contraceptives or hormone therapy that increase estrogen levels.

Remember as well that yeast and bacteria flourish in a damp, warm environment. So, if you fit into any of the above criteria, you can take steps to prevent yeast infections from occurring. Mayo Clinic and Healthline both recommend wearing slightly looser fitting underwear that has a cotton panel in the crotch, as well as avoiding super tight-fitting tights or leggings and being sure to change out of wet or damp workout clothing or swimsuits as soon as youre done. Additionally, refrain from taking extremely hot showers or baths, because the hot, wet environment can exacerbate the issue. You should also refrain from douching. The vagina is self-cleaning, and does not require help in its job. Douching the vagina can only cause worse issues.

You should definitely avoid having sex if you believe you may have a yeast infection of any kind. Bacteria thrives in moist environments, and genitals are the perfect breeding spot. Having sex with a partner may unbalance your partners pH, and you will be exposing them to the risk of infection as well. Its best to just wait it out. Mild infections can have symptoms disappear after only a few days of treatment, while more moderate to severe infections may last anywhere from one to three weeks.

If you think you may have a yeast infection, the best first step is to see a professional. The kind of doctor associated with genital health is a gynecologist for vaginas, and urologists specialize in penile care. Many options are available as well for those who wish to treat at home, such as antifungal treatments (here is a link for over-the-counter treatment of the penis). However, it should be acknowledged that you should check with your general practitioner to address any risks and seek medical attention if symptoms persist for more than the amount of time recommended on the package.

Do you have a question about sex, sexuality, or relationships? You can ask us to find you accurate and reliable information from experts by tweeting @SEATUTK, direct messaging @Sexweekut on Facebook or submitting a question to our anonymous Google form.

Columns and letters of The Daily Beacon are the views of the individual and do not necessarily reflect the views of the Beacon or the Beacon's editorial staff.

See the rest here:
Let's Talk About It: Yeast Infections - UT Daily Beacon

Recommendation and review posted by Bethany Smith

NewsReal LifeEva Echo came out as transgender to wife Pippa two years ago despite fearing it could mean their relationship was over

Tuesday, 3rd December 2019, 5:40 pm

Eva Echo, 39, and her wife Pippa Ng, 29, talk about how Eva's coming out as trans made their relationship stronger, as well as the mental health struggles she faced on her journey to self acceptance.

It was obvious what the customer in Eva's tattoo shop was doing. The smirk on his face after he took a sly snap of her on his phone said it all. "He was clearly sending snaps to his friends, probably telling them, Have a look at this freak," she said.

She knew she stood out. "At that time, adopting an androgynous look and wearing make-up was a sort of comfortable middle ground for me. But I couldnt even say the word transgender, let alone admit it to myself."

The truth was that being called by the male name she was given at birth, and the male body she was born into, had been the root of years of torment. The multiple suicide attempts five major ones that led to hospitalisations. An eating disorder. The self-loathing. The denial.

"I'd always tried to imitate my friends and be 'one of the lads'," she said. "But I wasn't and my mental health problems were because I had no solid sense of identity, of who I really was as a person."

Then at the age of 37, there in the shop was a reminder of everything she'd been afraid of social rejection, ridicule, discrimination and abuse. Transphobia. But the way forward suddenly became clearer.

This guy really made me wake up and question who I was. I thought, how do people see me, when I dont even know how I see me? If people are already laughing at me, then fuck it, why not go the whole hog?"

Coming out

Eva opened up to her best friend Christine, who was "super supportive", which gave her the courage to tell Pippa, who she'd met at a gig six years ago, and married eight months later.

But Pippa had dated only men. I knew I needed to tell Pippa, but I was a nervous wreck. She already accepted me for who I was and the way I looked. So that made it easier to come out to her. But I know people who come out to their partners and they say it's okay, then some time later it all falls apart. I thought, what if it's really not okay for her?"

Eva swigged back a few glugs of vodka and took a deep breath. There was no going back once the words were said. "I told her everything. She wasn't even surprised. She just sort of shrugged and said, I know'.

It was huge for me. Shes the most important thing in my life. She wasnt angry. Id built things up to be so horrific that it was the ultimate turning point for me. To be accepted for exactly who you are makes you feel really truly loved. Pippa is very protective over me and gets upset if anyone stares at me."

Pippa says she always had a strong feeling Eva was struggling with her gender. "It's not like Eva was this big, burly man who dropped a bombshell about wearing my clothes behind closed doors. I'd never gone for butch men."

And while Pippa never labelled herself, she said she identifies with being pansexual, that is knowing she is attracted to people regardless of their sex or gender identity. "I always dated men and have never dated a woman. But I was aware that was because I'd never met a woman who I felt really attracted to.

"For me love is love, as they say. I really like the phrase 'Love is hearts not parts'. I was just relieved that Eva could now put a name to what was making her so unhappy. And I look and dress a bit 'different' myself. So I can identify with that. Both of us feel sure that we don't want children, so thankfully that's not an issue for us."

Journey to acceptance

And so almost immediately, Eva, from near Birmingham, took steps to begin her transition. But after going to her GP and being referred to a gender identity clinic (GIC) , she was devastated to be told the waiting list had jumped to two-and-a-half years. Like many trans people struggling to access timely help, she considered buying potentially-dangerous hormones online.

"The wait was just for an initial appointment, it would have been longer for me to have anything done. I feel like I knew from the age of four, but it can take trans people like myself years and years to get to a place of realising you're in the wrong body. Then you take this big leap and you expect the help to be there. But every year that passed was another year of not being me."

Fearful of suffering further mental health problems, she sought a diagnosis and hormone therapy from private firm Gender Care, where the waiting list was just three months. She also recently underwent facial feminisation surgery with surgeon Christopher Inglefield, who featured in ITV documentary Transformation Street.

Eva said she isn't on speaking terms with her parents, who have struggled to accept the changes. "I'm Chinese, and while I think culture has played a role, I know of more open minded Chinese families. I understand that they came over from Hong Kong back in the day when there was more open racism and they have struggled themselves with feeling like they fit in."

Pippa's family meanwhile have accepted Eva with open arms. "My dad was brilliant straight away, my mum was too, it just took her a bit longer to remember to refer to Eva as she, or her 'daughter-in-law'.

"At a family do I my granddad was great. He called Eva by her original male name and I explained she was called Eva now. He just hugged and kissed her like he would any woman. If someone of that generation can embrace it, that gives us hope."

You can read Eva's blog where she shares about her transition here.

Do you have a story about relationships to share? Email claudia.tanner@inews.co.uk

There are just seven GICs in England London being the main one, as well as Sheffield, Leeds, Newcastle, Daventry, Nottingham and Exeter to serve a UK trans population estimated to be as large as 660,000.

Record demand for help from NHS gender identity clinics has seen waiting times reach more than two years, research has shown.

Providers of such services say they are not adequately funded by NHS England, according to an investigation by Health Service Journal.

There are no official waiting time statistics, but four of the six providers in England shared their data with the publication which discovered providers are reporting average waiting times of more than two years.

Tavistock and Portman Foundation Trust, the countrys largest provider of transgender services, said back in August when the report came out that its waiting list for a first appointment, at 5,717, is at an all-time high.

One expert clinician says his service is four times over subscribed in terms of what its funded to deliver.

NHS England said its budget for gender identity services increased to 38m in 2019-20, compared to 34m the previous year. However, it acknowledged the problems and said it will be piloting new delivery models.

Campaigners say transgender people are being put at greater risk of suicide and self-harm because of long waits.

A spokesperson for the Tavistock said that in addition to an "an unprecedented increase" in the number of referrals to its service, they are also having to deal with a high staff turnover and patients cancelling appointments. A statement read: "We are aware that the waiting time for a first appointment at GICS is currently growing and are doing all we can to address this."

Original post:
Relationship diaries: 'Love is about hearts not parts' says wife on accepting her partner as trans - inews

Recommendation and review posted by Bethany Smith

Market Research Hub (MRH) has actively discoursed a new study titled Global Bone Marrow Transplant Rejection Treatment Market Professional Survey Report 2019, added to its vast online repository. The main motive of this assessment is to present clear insights about the growth factor experienced across the Bone Marrow Transplant Rejection Treatment Market during the forecast period. Readers can access vital information associated to prime market facets such as market size, market share, market drivers, future trends, challenges, opportunities and sales channels. Furthermore, the availability of competitive developments including leading market players make the report a rich data source for investors and new entrants.

Get Sample Copy @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2560597

The global Bone Marrow Transplant Rejection Treatment market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.

This report focuses on Bone Marrow Transplant Rejection Treatment volume and value at global level, regional level and company level. From a global perspective, this report represents overall Bone Marrow Transplant Rejection Treatment market size by analyzing historical data and future prospect.

Regionally, this report categorizes the production, apparent consumption, export and import of Bone Marrow Transplant Rejection Treatment in North America, Europe, China, Japan, Southeast Asia and India.

For each manufacturer covered, this report analyzes their Bone Marrow Transplant Rejection Treatment manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:Bellicum Pharmaceuticals, Inc.Bio-Cancer Treatment International LimitedBiogen IncBoryung Pharmaceutical Co., Ltd.Bristol-Myers Squibb CompanyCantex Pharmaceuticals, Inc.Capricor Therapeutics, Inc.Cell Source, Inc.Cell2B S.A.CellECT Bio, Inc.Cleveland BioLabs, Inc.Compugen Ltd.Cynata Therapeutics LimitedCytodyn Inc.Dompe Farmaceutici S.p.A.Dr. Falk Pharma GmbHEscape Therapeutics, Inc.F. Hoffmann-La Roche Ltd.Fate Therapeutics, Inc.Generon (Shanghai) Corporation Ltd.

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeAzathioprineAdrenocorticotropic HormoneCyclophosphamideCyclosporine AOthers

Segment by ApplicationHospitalClinicOthers

Browse Complete Report @ https://www.marketresearchhub.com/report/global-bone-marrow-transplant-rejection-treatment-market-professional-survey-report-2019-report.html

Table of Contents

Executive Summary1 Industry Overview of Bone Marrow Transplant Rejection Treatment1.1 Definition of Bone Marrow Transplant Rejection Treatment1.2 Bone Marrow Transplant Rejection Treatment Segment by Type1.2.1 Global Bone Marrow Transplant Rejection Treatment Production Growth Rate Comparison by Types (2014-2025)1.2.2 Azathioprine1.2.3 Adrenocorticotropic Hormone1.2.4 Cyclophosphamide1.2.5 Cyclosporine A1.2.6 Others1.3 Bone Marrow Transplant Rejection Treatment Segment by Applications1.3.1 Global Bone Marrow Transplant Rejection Treatment Consumption Comparison by Applications (2014-2025)1.3.2 Hospital1.3.3 Clinic1.3.4 Others1.4 Global Bone Marrow Transplant Rejection Treatment Overall Market1.4.1 Global Bone Marrow Transplant Rejection Treatment Revenue (2014-2025)1.4.2 Global Bone Marrow Transplant Rejection Treatment Production (2014-2025)1.4.3 North America Bone Marrow Transplant Rejection Treatment Status and Prospect (2014-2025)1.4.4 Europe Bone Marrow Transplant Rejection Treatment Status and Prospect (2014-2025)1.4.5 China Bone Marrow Transplant Rejection Treatment Status and Prospect (2014-2025)1.4.6 Japan Bone Marrow Transplant Rejection Treatment Status and Prospect (2014-2025)1.4.7 Southeast Asia Bone Marrow Transplant Rejection Treatment Status and Prospect (2014-2025)1.4.8 India Bone Marrow Transplant Rejection Treatment Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis2.1 Raw Material and Suppliers2.2 Manufacturing Cost Structure Analysis of Bone Marrow Transplant Rejection Treatment2.3 Manufacturing Process Analysis of Bone Marrow Transplant Rejection Treatment2.4 Industry Chain Structure of Bone Marrow Transplant Rejection Treatment

3 Development and Manufacturing Plants Analysis of Bone Marrow Transplant Rejection Treatment3.1 Capacity and Commercial Production Date3.2 Global Bone Marrow Transplant Rejection Treatment Manufacturing Plants Distribution3.3 Major Manufacturers Technology Source and Market Position of Bone Marrow Transplant Rejection Treatment3.4 Recent Development and Expansion Plans4 Key Figures of Major Manufacturers4.1 Bone Marrow Transplant Rejection Treatment Production and Capacity Analysis4.2 Bone Marrow Transplant Rejection Treatment Revenue Analysis4.3 Bone Marrow Transplant Rejection Treatment Price Analysis4.4 Market Concentration Degree

Enquire More about This Report @ https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=2560597

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like Pharmaceutical Market and analysis. MRHs expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street,

Albany, NY 12207,

United States

Toll Free: 800-998-4852 (US-Canada)

Email: [emailprotected]

Website: http://www.marketresearchhub.com/

Read Industry News at: https://www.industrynewsanalysis.com/

See the article here:
Bone Marrow Transplant Rejection Treatment Market Status, Types and Applications and Forecast to 2025 - News Description

Recommendation and review posted by Bethany Smith

DUBLIN, Nov. 28, 2019 /PRNewswire/ -- The "Genome Editing Services Market-Focus on CRISPR 2019-2030" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographical regions.

Currently, there is an evident increase in demand for complex biological therapies (including regenerative medicine products), which has created an urgent need for robust genome editing techniques. The biopharmaceutical pipeline includes close to 500 gene therapies, several of which are being developed based on the CRISPR technology.

Recently, in July 2019, a first in vivo clinical trial for a CRISPR-based therapy was initiated. However, successful gene manipulation efforts involve complex experimental protocols and advanced molecular biology centered infrastructure. Therefore, many biopharmaceutical researchers and developers have demonstrated a preference to outsource such operations to capable contract service providers.

Consequently, the genome editing contract services market was established and has grown to become an indispensable segment of the modern healthcare industry, offering a range of services, such as gRNA design and construction, cell line development (involving gene knockout, gene knockin, tagging and others) and transgenic animal model generation (such as knockout mice). Additionally, there are several players focused on developing advanced technology platforms that are intended to improve/augment existing gene editing tools, especially the CRISPR-based genome editing processes.

Given the rising interest in personalized medicine, a number of strategic investors are presently willing to back genetic engineering focused initiatives. Prevalent trends indicate that the market for CRISPR-based genome editing services is likely to grow at a significant pace in the foreseen future.

Report Scope

One of the key objectives of the report was to evaluate the current opportunity and the future potential of CRISPR-based genome editing services market. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2019-2030.

In addition, we have segmented the future opportunity across [A] type of services offered (gRNA construction, cell line engineering and animal model generation), [B] type of cell line used (mammalian, microbial, insect and others) and [C] different geographical regions (North America, Europe, Asia Pacific and rest of the world).

To account for the uncertainties associated with the CRISPR-based genome editing services market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights generated from both secondary and primary research. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Topics Covered

1. PREFACE1.1. Scope of the Report1.2. Research Methodology1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION3.1. Context and Background3.2. Overview of Genome Editing3.3. History of Genome Editing3.4. Applications of Genome Editing3.5. Genome Editing Techniques3.5.1. Mutagenesis3.5.2 Conventional Homologous Recombination3.5.3 Single Stranded Oligo DNA Nucleotides Homologous Recombination3.5.4. Homing Endonuclease Systems (Adeno Associated Virus System)3.5.5. Protein-based Nuclease Systems3.5.5.1. Meganucleases3.5.5.2. Zinc Finger Nucleases3.5.5.3. Transcription Activator-like Effector Nucleases3.5.6. DNA Guided Systems3.5.6.1. Peptide Nucleic Acids3.5.6.2. Triplex Forming Oligonucleotides3.5.6.3. Structure Guided Endonucleases3.5.7. RNA Guided Systems3.5.7.1. CRISPR-Cas93.5.7.2. Targetrons3.6. CRISPR-based Genome Editing3.6.1. Role of CRISPR-Cas in Adaptive Immunity in Bacteria3.6.2. Key CRISPR-Cas Systems3.6.3. Components of CRISPR-Cas System3.6.4. Protocol for CRISPR-based Genome Editing3.7. Applications of CRISPR3.7.1. Development of Therapeutic Interventions3.7.2. Augmentation of Artificial Fertilization Techniques3.7.3. Development of Genetically Modified Organisms3.7.4. Production of Biofuels3.7.5. Other Bioengineering Applications3.8. Key Challenges and Future Perspectives

4. CRISPR-BASED GENOME EDITING SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE4.1. Chapter Overview4.2. CRISPR-based Genome Editing Service Providers: Overall Market Landscape4.2.3. Analysis by Type of Service Offering4.2.4. Analysis by Type of gRNA Format4.2.5. Analysis by Type of Endonuclease4.2.6. Analysis by Type of Cas9 Format4.2.7. Analysis by Type of Cell Line Engineering Offering4.2.8. Analysis by Type of Animal Model Generation Offering4.2.9. Analysis by Availability of CRISPR Libraries4.2.10. Analysis by Year of Establishment4.2.11. Analysis by Company Size4.2.12. Analysis by Geographical Location4.2.13. Logo Landscape: Distribution by Company Size and Location of Headquarters

5. COMPANY COMPETITIVENESS ANALYSIS5.1. Chapter Overview5.2. Methodology5.3. Assumptions and Key Parameters5.4. CRISPR-based Genome Editing Service Providers: Competitive Landscape5.4.1. Small-sized Companies5.4.2. Mid-sized Companies5.4.3. Large Companies

6. COMPANY PROFILES6.1. Chapter Overview6.2. Applied StemCell6.2.1. Company Overview6.2.2. Service Portfolio6.2.3. Recent Developments and Future Outlook6.3. BioCat6.4. Biotools6.5. Charles River Laboratories6.6. Cobo Scientific6.7. Creative Biogene6.8. Cyagen Biosciences6.9. GeneCopoeia6.10. Horizon Discovery6.11. NemaMetrix6.12. Synbio Technologies6.13. Thermo Fisher Scientific

7. PATENT ANALYSIS7.1. Chapter Overview7.2. Scope and Methodology7.3. CRISPR-based Genome Editing: Patent Analysis7.3.1. Analysis by Application Year and Publication Year7.3.2. Analysis by Geography7.3.3. Analysis by CPC Symbols7.3.4. Emerging Focus Areas7.3.5. Leading Players: Analysis by Number of Patents7.4. CRISPR-based Genome Editing: Patent Benchmarking Analysis7.4.1. Analysis by Patent Characteristics7.5. Patent Valuation Analysis

8. ACADEMIC GRANT ANALYSIS8.1. Chapter Overview8.2. Scope and Methodology8.3. Grants Awarded by the National Institutes of Health for CRISPR-based8.3.1. Year-wise Trend of Grant Award8.3.2. Analysis by Amount Awarded8.3.3. Analysis by Administering Institutes8.3.4. Analysis by Support Period8.3.5. Analysis by Funding Mechanism8.3.6. Analysis by Type of Grant Application8.3.7. Analysis by Grant Activity8.3.8. Analysis by Recipient Organization8.3.9. Regional Distribution of Grant Recipient Organization8.3.10. Prominent Project Leaders: Analysis by Number of Grants8.3.11. Emerging Focus Areas8.3.12. Grant Attractiveness Analysis

9. CASE STUDY: ADVANCED CRISPR-BASED TECHNOLOGIES/SYSTEMS AND TOOLS9.1. Chapter Overview9.2. CRISPR-based Technology Providers9.2.1. Analysis by Year of Establishment and Company Size9.2.2. Analysis by Geographical Location and Company Expertise9.2.3. Analysis by Focus Area9.2.4. Key Technology Providers: Company Snapshots9.2.4.1. APSIS Therapeutics9.2.4.2. Beam Therapeutics9.2.4.3. CRISPR Therapeutics9.2.4.4. Editas Medicine9.2.4.5. Intellia Therapeutics9.2.4.6. Jenthera Therapeutics9.2.4.7. KSQ Therapeutics9.2.4.8. Locus Biosciences9.2.4.9. Refuge Biotechnologies9.2.4.10. Repare Therapeutics9.2.4.11. SNIPR BIOME9.2.5. Key Technology Providers: Summary of Venture Capital Investments9.3. List of CRISPR Kit Providers9.4. List of CRISPR Design Tool Providers

10. POTENTIAL STRATEGIC PARTNERS10.1. Chapter Overview10.2. Scope and Methodology10.3. Potential Strategic Partners for Genome Editing Service Providers10.3.1. Key Industry Partners10.3.1.1. Most Likely Partners10.3.1.2. Likely Partners10.3.1.3. Less Likely Partners10.3.2. Key Non-Industry/Academic Partners10.3.2.1. Most Likely Partners10.3.2.2. Likely Partners10.3.2.3. Less Likely Partners

11. MARKET FORECAST11.1. Chapter Overview11.2. Forecast Methodology and Key Assumptions11.3. Overall CRISPR-based Genome Editing Services Market, 2019-203011.4. CRISPR-based Genome Editing Services Market: Distribution by Regions, 2019-203011.4.1. CRISPR-based Genome Editing Services Market in North America, 2019-203011.4.2. CRISPR-based Genome Editing Services Market in Europe, 2019-203011.4.3. CRISPR-based Genome Editing Services Market in Asia Pacific, 2019-203011.4.4. CRISPR-based Genome Editing Services Market in Rest of the World, 2019-203011.5. CRISPR-based Genome Editing Services Market: Distribution by Type of Services, 2019-203011.5.1. CRISPR-based Genome Editing Services Market for gRNA Construction, 2019-203011.5.2. CRISPR-based Genome Editing Services Market for Cell Line Engineering, 2019-203011.5.3. CRISPR-based Genome Editing Services Market for Animal Model Generation, 2019-203011.6. CRISPR-based Genome Editing Services Market: Distribution by Type of Cell Line, 2019-203011.6.1. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines, 2019-203011.6.2. CRISPR-based Genome Editing Services Market for Microbial Cell Lines, 2019-203011.6.3. CRISPR-based Genome Editing Services Market for Other Cell Lines, 2019-2030

12. SWOT ANALYSIS12.1. Chapter Overview12.2. SWOT Analysis12.2.1. Strengths12.2.2. Weaknesses12.2.3. Opportunities12.2.4. Threats12.2.5. Concluding Remarks

13. EXECUTIVE INSIGHTS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/78rwbq

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

See original here:
Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool - PRNewswire

Recommendation and review posted by Bethany Smith

Dec. 2, 2019 10:30 UTC

CAMBRIDGE, Mass. & SEATTLE--(BUSINESS WIRE)-- Cyrus Biotechnology, Inc., and the Broad Institute of MIT and Harvard have embarked on a scientific collaboration to optimize CRISPR for use in developing novel human therapeutics.

CRISPR allows for the highly specific and rapid modification of DNA in a genome, which can dramatically accelerate the drug discovery process.

Feng Zhang will be the principal investigator for the Broad for the collaboration. He is also an investigator of the Howard Hughes Medical Institute (HHMI).

Together, researchers from Cyrus and Broad will work together to mitigate the possibility of the body mounting an immune response against CRISPR. The teams are committed to making the results of their collaboration broadly available for research to help ensure that therapeutic development bringing this technology to the clinic has the best chance of success, while also considering important ethical and safety concerns. The teams have also committed to publishing their results in peer reviewed journals and to make this work freely available to the non-profit and academic scientific community.

Issi Rozen, chief business officer at the Broad Institute, said, Broad researchers and their collaborators have pioneered the development and sharing of new genome editing tools, such as CRISPR-Cas9, which are revolutionizing and accelerating nearly every aspect of disease research and drug discovery around the world. With this collaboration, scientists will continue to improve the technology towards new tools and therapeutics, important to benefiting patients in the long term.

Cyrus CEO Dr. Lucas Nivn added, We have validated our computational deimmunization platform in a variety of systems, and now seek to apply it where it can make a major impact. Given the extensive therapeutic possibilities of CRISPR systems, and the leading position the Broad Institute and Dr. Zhang hold, we are very excited to work in partnership with them to make these molecules more amenable for use in humans with maximal efficacy and minimal side effects.

Cyrus provides commercial and partnered access to Rosetta, which is the worlds leading protein modeling and design software platform. Rosetta has been used to direct the computational design of multiple biologic molecules that have advanced to both pre-clinical and clinical development. Among these are drugs being developed by companies including PVP Biologics, Tocagen, Lyell and others.

About Cyrus Biotechnology

Cyrus Biotechnology, Inc. is a privately-held Seattle-based biotechnology software company offering software and partnerships for protein engineering to accelerate discovery of biologics and small molecules for the Biotechnology, Pharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus methods are based on the Rosetta software from Prof. David Bakers laboratory at the University of Washington and HHMI, the most powerful protein engineering software available. Cyrus customers include 13 of the top 20 Global Pharmaceutical firms and is financed by leading investors in both Technology and Biotechnology, including Trinity Ventures, Orbimed, Springrock Ventures, Alexandria Venture Investments, and W Fund.

Home

View source version on businesswire.com: https://www.businesswire.com/news/home/20191202005078/en/

See the original post:
Cyrus Biotechnology and the Broad Institute of MIT and Harvard Launch Multi-Target Collaboration to Develop Optimized CRISPR Gene Editing Technology -...

Recommendation and review posted by Bethany Smith

Global CRISPR in Agriculture Market valued approximately USD XX million in 2016 is anticipated tgrow with a healthy growth rate of more than XX% over the forecast period 2017-2025. Increasing demand in drug discovery, late pregnancies leading tbirth disorders, synthetic genes leading the way; aging genetic disorders and investment in path breaking research technology are the drivers for CRISPR Market. Drug discovery technology market plays a dominant role in boosting the CRISPR market. Genome editing has been revolutionized with the discovery of the CRISPR-CAS9 system from streptococcus pyogenes.

Request a Sample Copy of this[emailprotected]https://www.orbisresearch.com/contacts/request-sample/2129000

The objective of the study is tdefine market sizes of different segments & countries in recent years and tforecast the values tthe coming eight years. The report is designed tincorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report alscaters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall alsincorporate available opportunities in micrmarkets for stakeholders tinvest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Crop Type:Staple CropsFruits & VegetablesOrnamentalsOthers

By Regions:North AmericaU.S.CanadaEuropeUKGermanyAsia PacificChinaIndiaJapanLatin AmericaBrazilMexicoRest of the World

To make an enquiry on[emailprotected]https://www.orbisresearch.com/contacts/enquiry-before-buying/2129000

Furthermore, years considered for the study are as follows:Historical year 2015Base year 2016Forecast period 2017 t2025

Some of the key manufacturers involved in the market are:

DuPont, Cibus, Monsanto, Bayer AG. Acquisitions and effective mergers are some of the strategies adopted by the key manufacturers. New product launches and continuous technological innovations are the key strategies adopted by the major players.

Browse full[emailprotected]https://www.orbisresearch.com/reports/index/global-crispr-in-agriculture-market-forecasts-2017-2025

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:

Hector Costello

Senior Manager Client Engagements

4144N Central Expressway,

Suite 600, Dallas,

Texas 75204, U.S.A.

Phone No:+1 (214) 884-6817; +912064101019

Email ID:[emailprotected]

Read the original:
CRISPR in Agriculture Market 2019 by Services, Application, Key Players, Size, Trends and Forecast 2025 - Downey Magazine

Recommendation and review posted by Bethany Smith

Cancer | One of the most common disease in the world

In what may prove as a breakthrough in the treatment of leukaemia and other blood diseases, scientists at UCLA have discovered a protein produced by a gene known as MLLT3 and its connection to the multiplication of human blood stem cells.

The discovery which was published in a study is very much significant as cancers such as leukaemia can be effectively treated using blood stem cells, also known as Hematopoietic stem cells (HSCs), produced outside the human body and could serve as an alternative to existing treatment options such as bone marrow transplants.

Self-renewal is the process by which stem cells divide to create more cells. The study focused on a specific type of the kind: Hematopoietic stem cells (HSCs) which are present within the bone marrow where along with self-renewal, they also produce different types of blood cells such as red and white by transforming into them.

Placing HSCs in laboratory dishes after their removal from the bone marrow causes then to lose their ability to self-renew, and they either transform into other blood types or perish. It is this process that the scientists studied. Through a series of steps, the researchers studied the genes that shutdown as the cells lost their capacity to self-renew.

They discovered that the HSCs' ability to self-renew corresponded with the expression of a gene called MLLT3. They also found that MLLT3 generated a protein that instructed HSCs to retain their capacity to self-renew. As the cells divide, the protein works along with other regulatory proteins to keep vital components of the HSCs' functioning.

Employing a viral vector the researchers tried to ascertain if maintaining the MLLT3 protein levels in lab dishes would help improve the self-renewing abilities of HSCs. A viral vector is a specially designed virus that transfers genetic information to the nucleus of a cell without giving rise to a disease. Using the vector, the scientists introduced an active MLLT3 gene into HSCs. They found that there was nearly a twelvefold multiplication of working HSCs in lab dishes.

"If we think about the amount of blood stem cells needed to treat a patient, that's a significant number," said Dr. Hanna Mikkola, a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, and senior author of the study, to the UCLA Newsroom.

The UCLA scientists observed that the use of 'small molecules' organic compounds that help in the multiplication of human HSCs, improved self-renewal in general. However, the cells were unable to maintain stable MLLT3 levels and did not perform well when implanted into mice.

"Our method, which exposes blood stem cells to the small molecules and also inserts an active MLLT3 gene, created blood stem cells that integrated well into mouse bone marrow, efficiently produced all blood cell types and maintained their self-renewing ability," said Vincenzo Calvanese, a UCLA project scientist and the study's co-corresponding author, to the UCLA Newsroom.

The team noted that the self-renewal of HSCs caused by MLLT3 was at a safe rate. This means that they did not acquire potent characteristics such as mutation or excessive multiplication, or the production aberrant cells that can cause leukaemia.

Determining which proteins and constituents within the DNA of the HSCs affect the activation and deactivation of MLLT3 is the next step for the team. Also, understanding the regulation of the process using components in the lab dishes is another step. The information gathered may help find ways in which MLLT3 could be switched on and off without employing a viral vector.

Read more:
Protein that can help treatment of leukemia identified, UCLA scientists upbeat - International Business Times, Singapore Edition

Recommendation and review posted by Bethany Smith

2 December 2019

Stem cell therapies may become redundant in repairing cardiac function after a heart attack, suggests a new study in mice.

It showed how stem cell treatments can heal hearts by triggering an immune response which can be achieved by using a chemical instead.

'This work is paradigm-shifting because it demonstrates a mechanism to explain a perplexing phenomenon that has intrigued cardiologists as a result of decades of cardiac stem cell trials,' Dr Jonathan Epstein at the University of Pennsylvania's Perelman School of Medicine in Philadelphia told The Scientist.

Stem cell therapies to repair damaged heart tissue are currently being tested in human clinical trials. In these treatments, human stem cells are injected into the heart and this leads to an improvement in heart function. However, how this works is not fully understood.

One possibility is that the injected stem cells are incorporated into the heart tissue and repair the damage. However, the latest study, published in the journal Nature, suggests that this may not be the case. Instead, the study indicated that the repair is actually a result of triggering the innate immune response.

Researchers injected different types of stem cell or a chemical inducer (zymosan) of the innate immune response into an experimental mouse model of heart disease. They saw improvement in heart function that was similar in all cases, and showed that this repair occurs via activation of macrophage cells of the innate immune system.

'The innate immune response acutely altered cellular activity around the injured area of the heart so that it healed with a more optimised scar and improved contractile properties,' said Dr Jeffery Molkentin at the University of Cincinnati and Cincinnati Children's Hospital Medical Centre, Ohio, who led the study. 'The implications of our study are very straightforward and present important new evidence about an unsettled debate in the field of cardiovascular medicine.'

The work could open up new possibilities for optimising the treatments currently in development, as well as alternative new therapies.

'If there is a chemical off-the-shelf, it would be a much more feasible therapy [than stem cell transplants],'Dr Kory Lavine at Washington University in St Louis, Missouri, told Nature News.

Continue reading here:
Stem cells may trigger immune repair to mend hearts - BioNews

Recommendation and review posted by Bethany Smith

VANCOUVER, British Columbia, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Novoheart (Novoheart or the Company) (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company, is pleased to announce a collaboration with global biopharmaceutical company AstraZeneca, in an effort to develop the worlds first human-specific in vitro, functional model of heart failure with preserved ejection fraction (HFpEF), a common condition especially among the elderly and in women, with the reported prevalence approaching 10% in women over the age of 80 years.1

Heart failure (HF) is a global pandemic with an estimated 64.3 million cases worldwide in 2017, with an increasing trend in prevalence2. The annual global economic burden of HF is estimated at over US$100 billion3. Accounting for approximately 50% of HF cases, HFpEF in particular is a major and growing public health problem worldwide, with its pathological mechanisms and diverse etiology poorly understood. Due to these complexities, models of the disease available to date, including various animal models, have limited ability to mimic the clinical presentation of HFpEF4. Therefore, drug developers lack an effective tool for preclinical testing of drug candidates for efficacy, and as a result, clinical outcomes for HFpEF have not improved over the last decades, with no effective therapies available.

In collaboration with the Cardiovascular, Renal and Metabolism therapy area of AstraZeneca, the initial phase of the project aims to establish a new in vitro model, leveraging Novohearts proprietary 3-D human ventricular cardiac organoid chamber (hvCOC) technology, that reproduces key phenotypic characteristics of HFpEF. Also known as human heart-in-a-jar, the hvCOC is the only human engineered heart tissue available on the market to date that enables clinically informative assessment of human cardiac pump performance including ejection fraction and developed pressure. Unlike animal models, engineered hvCOCs can be fabricated with specific cellular and matrix compositions, and patient-specific human induced pluripotent stem cells (iPSCs), that allow control over their physical and mechanical properties to mimic those observed in HFpEF patient hearts. Together with Novohearts proprietary hardware and software, this aims to provide a unique assay for understanding the mechanisms of HFpEF, identification of new therapeutic targets, and assessment of novel therapeutics for treating HFpEF patients. Novoheart will exclusively own the intellectual property rights to the newly developed HFpEF hvCOC model.

We are delighted to partner with AstraZeneca, an organization which has long invested in cardiovascular research and is committed to bringing new therapeutic solutions to patients with heart failure, said Novoheart CSO, Dr. Kevin Costa. We look forward to co-developing this new HFpEF hvCOC model into a powerful new tool in the worldwide battle against heart failure.

Regina Fritsche Danielson, Senior Vice President, Head of Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, said, There are significant unmet treatment needs in patients with heart failure with preserved ejection fraction. By combining Novohearts proprietary hvCOC model with our expertise in heart failure, we aim to create the first in vitro model reproducing phenotypic characteristics of heart failure with preserved ejection fraction. This could bridge the gap between in vivo animal models and clinical trials to help accelerate the drug discovery process by providing human-specific preclinical data.

1 Heart Fail Clin. 2014; 10(3):377388.2 Lancet. 2018; 392:1789-1858.3 Int J Cardiol. 2014; 171(3):368-76.4 JACC Basic Transl Sci. 2017; 2(6):770-789.

About Novoheart:

Novoheart is a global stem cell biotechnology company pioneering an array of next-generation human heart tissue prototypes. It is the first company in the world to have engineered miniature living human heart pumps that can revolutionize drug discovery, helping to save time and money for developing new therapeutics. Also known as 'human heart-in-a-jar', Novohearts bio-artificial human heart constructs are created using state-of-the-art and proprietary stem cell and bioengineering approaches and are utilized by drug developers for accurate preclinical testing of the effectiveness and safety of new drugs, maximizing the successes in drug discovery whilst minimizing costs and harm caused to patients. With the recent acquisition of Xellera Therapeutics Limited for manufacturing Good Manufacturing Product (GMP)-grade clinical materials, Novoheart is now developing gene- and cell-based therapies as well as next-generation therapeutics for cardiac repair or regeneration.

For further information, please contact:Ronald Li, CEOinfo@novoheart.com

For media enquiries or interviews, please contact:Media Relationsmedia@novoheart.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in under the heading Risk Factors in Novohearts annual information form for the year ended June 30, 2019 or other reports and filings with the TSX Venture Exchange and applicable Canadian securities regulators. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and the respective companies undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements.

Read the original here:
Novoheart to Co-develop First of its Kind Human Heart-in-a-Jar Model of Heart Failure with AstraZeneca - GlobeNewswire

Recommendation and review posted by Bethany Smith

This report studies the Global Canine Stem Cell Therapy market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Canine Stem Cell Therapy market by companies, region, type and end-use industry.

The non-invasive stem cell obtaining procedure, augmented possibility of accomplishing high quality cells, and lower price of therapy coupled with high success rate of positive outcomes have collectively made allogeneic stem cell therapy a preference for veterinary physicians. Moreover, allogeneic stem cell therapy is 100% safe, which further supports its demand on a global level. Pet owners are identified to prefer allogeneic stem cell therapy over autologous therapy, attributed to its relatively lower costs and comparative ease of the entire procedure.

Avail a Sample Copy before Purchase:

https://www.marketinsightsreports.com/reports/07111356900/global-canine-stem-cell-therapy-market-size-status-and-forecast-2019-2025/inquiry?Mode=21

The prominent players in the global Canine Stem Cell Therapy market are:

VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet

Canine Stem Cell TherapyMarket segment by Types:

Allogeneic Stem CellsAutologous Stem cells

Canine Stem Cell TherapyMarket segment by Applications:Veterinary HospitalsVeterinary ClinicsVeterinary Research Institutes Top of Form

Global Canine Stem Cell Therapy Market Segmentation by Region:

North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, South Korea, Australia, Indonesia, Malaysia, Philippines, Thailand, Vietnam, Europe, Germany, France, UK, Italy, Russia, Rest of Europe, Central & South America

Scope of the Report

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry.

The report is designed to incorporate both qualitative and quantitative aspects of the Canine Stem Cell Therapy Market with respect to each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as major drivers & restraining factorswhich will define the future growth of the market.

Get Exclusive Discount at:

https://www.marketinsightsreports.com/reports/07111356900/global-canine-stem-cell-therapy-market-size-status-and-forecast-2019-2025/discount?Mode=21

-Identify the current and future prospects of the global Canine Stem Cell Therapy market in the developed and emerging markets

-Analyse various perspectives of the market with the help of Porters five forces analysis

-Information about the growth of the various material, type, and application that are expected to dominate the market

-Regional and country analysis of the market

-Identify the latest developments, market shares, and strategies employed by the major market players

-3 months analyst support, along with the Market Estimate sheet (in Excel)

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyses key emerging trends and their impact on present and future development.

The research includes historic data from 2013 to 2018, and forecast to 2025 which makes the reports an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts, and other people looking for key industry data in readily accessible documents with clearly presented tables and graphs.

Contact Us:

Phone: + 1704 266 3234

Mob: +91-750-707-8687

sales@marketinsightsreports.com

irfan@marketinsightsreports.com

See the rest here:
Canine Stem Cell Therapy Market In Depth Research and Overview 2019 to 2025 - The Chicago Sentinel

Recommendation and review posted by Bethany Smith